Andrew Weiss
Head of Investor Relations and Corporate Communications, Member of the Idorsia Leadership Team at Idorsia Pharmaceuticals Ltd - Allschwil, Basel Landschaft, CH
Andrew Weiss's Colleagues at Idorsia Pharmaceuticals Ltd
Barbara Channer
Director Analytical Development Quality Control Drug Substance Clinical
Philippe Panchaud
Associate Director, Project Leader - Preclinical Development Project Management
Andrew Weiss's Contact Details
+41 58 844 10 10
Idorsia Pharmaceuticals Ltd
Andrew Weiss's Company Details
The purpose of Idorsia is to discover, develop, and commercialize innovative medicines to help more patients. We have more ideas, we see more opportunities, and we want to transform the horizon of therapeutic options. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered in Switzerland – a biotech-hub of Europe – Idorsia is a high-potential biopharmaceutical company, specialized in the discovery, development and commercialization of innovative small molecules, with the aim of transforming the horizon of therapeutic options. See our LinkedIn community guidelines: https://www.idorsia.com/documents/com/policies-charters/idorsia-linkedin-community-guidelines.pdf Idorsia privacy policy: https://www.idorsia.com/system/legal-statements/privacy-policy